MAPT and Alzheimer disease: While Aβ42 likely plays a major role during early stages of the disease, it has been proposed that Tau pathology plays a prominent role in the symptomatic (late) stages of AD as a key driver of the neurodegeneration (Hyman, 2011; Holtzman et al., 2016).